EnhancedBio USA

EnhancedBio is a clinical-stage biotechnology company specializing in the development of innovative RNA-based therapeutics using its proprietary lipid nanoparticle (LNP) delivery platform, EN-LNP. The company's lead candidate, EN-001, is an siRNA-based treatment targeting Heat Shock Protein 47 (HSP47) for the treatment of liver cirrhosis, currently undergoing clinical evaluation. EnhancedBio's pipeline also includes mRNA-based therapies and vaccines aimed at various oncology and infectious disease indications, leveraging the EN-LNP technology to overcome traditional challenges in RNA stability and targeted delivery. Headquartered in South Korea with a dedicated US subsidiary, EnhancedBio USA, the company is positioned to advance its programs through global clinical trials and strategic partnerships. The firm focuses on addressing high unmet medical needs in fibrosis and cancer through precision genetic medicine.